(Reuters) – Mallinckrodt Plc (MNK.N) said on Thursday it planned to spin off its specialty generics business to shareholders by the second half of 2019, capping a two-year long effort to look for options for the unit.

The new company will also include constipation drug Amitiza, which Mallinckrodt added through its acquisition of Sucampo Pharmaceuticals last year.

Mallinckrodt was in talks with at least two India-based pharmaceutical firms, Aurobindo Pharma Ltd (ARBN.NS) and Intas Pharmaceuticals

Read More At Article Source | Article Attribution